Perhaps the next step in addressing your lymphoma should be in a different direction.
You've already gone through one or more rounds of treatments for Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL). But either your cancer has returned or has become resistant to your treatment, and you're considering your next step.
About MAHOGANY
The MAHOGANY clinical study offers a potential alternative second-line (or more) treatment for people like you with relapsed / refractory Follicular Lymphoma (R / R FL) or Marginal Zone Lymphoma (R / R MZL).
Unlike many other clinical studies, patients may be eligible for the MAHOGANY study even after just one previous treatment regimen.
An Unmet Need
There have been recent improvements in treatment options for people with R / R FL and R / R MZL. Nevertheless, there remains an unmet need for a less toxic, more effective treatment that results in longer remission and prolonged, progression-free survival. The Mahogany Study is designed to try to determine if the investigational treatments being studied may offer these benefits.
About the Investigational Treatments
The investigational treatments being evaluated in the Mahogany clinical study include two combinations of drugs. Both investigational treatments will combine Zanubrutinib with one of two anti-CD20 monoclonal antibodies — either with Obinutuzumab if you have R / R FL, or with Rituximab if you have R / R MZL.
We are trying to determine if these investigational treatments may be more effective and have fewer side effects than existing standard-of-care options.
All three drugs being evaluated in the Mahogany clinical study were previously approved by the FDA and EC for use individually to treat other forms of lymphoma.
Possible Benefits of Participation
If you choose to participate in the Mahogany clinical study, some of the benefits you may receive include:
Either the investigational drug plus the anti-CD20 antibodies or the standard-of-care treatment (Lenalidomide plus Rituximab).
Close care and monitoring from experts in R / R FL and R / R MZL.
Potential reimbursement for study-related travel and expenses.